2020-11-13T18:50:46-06:00 2019-12-31 346565596 ERNST & YOUNG US LLP 18101 VON KARMAN AVENUE SUITE 1700 IRVINE CA 92612 990 2019-01-01 954772979 CALIFORNIA HEART CENTER FOUNDATION CALI 3102488327 8536 WILSHIRE BOULEVARD SUITE 301 BEVERLY HILLS CA 90211 JON KOBASHIGAWA MD PRESIDENT 3102488327 2020-11-13 1 KARA ADAMS P00023315 9497942300 163.116.132.115 2020-11-13 16:44:28 PS P 5D66495798EA847DC80F6602DD5A7F057B72F91F 06B79B3CF97A39592A6D2AF2C723A31CE5AEA88B 2019 2021-01-29 14:40:06Z JON KOBASHIGAWA MD 8536 WILSHIRE BOULEVARD SUITE 301 BEVERLY HILLS CA 90211 2210596 0 X WWW.CALHEART.ORG X 2000 CA PROMOTE & DEVELOP EDUCATIONAL & SCIENTIFIC RESEARCH TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE. 5 3 0 3 0 0 1603657 1944292 221768 266304 0 0 3813 0 1829238 2210596 0 0 0 0 1399820 1599359 0 0 0 490463 601968 1890283 2201327 -61045 9269 43775 79180 207993 234130 -164218 -154950 X THE MISSION OF THE CALIFORNIA HEART CENTER FOUNDATION IS TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE THROUGH CLINICAL RESEARCH INITIATIVES AND EDUCATIONAL INITIATIVES. 0 0 1954029 0 266304 THE MISSION OF THE CALIFORNIA HEART CENTER FOUNDATION IS TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE THROUGH CLINICAL RESEARCH INITIATIVES AND EDUCATIONAL INITIATIVES. OUR EFFORTS INCLUDE THE PURSUIT OF COLLABORATIVE RESEARCH PROJECTS WHICH PROMOTE A DEEPER UNDERSTANDING OF DISEASE PROGRESSION AND TEST THE EFFICACY OF NEW STRATEGIES FOR DIAGNOSIS AND TREATMENT. AREAS OF RESEARCH CURRENTLY BEING PURSUED INCLUDE NON-INVASIVE METHODS TO DETECT ORGAN REJECTION, NOVEL IMMUNOSUPPRESSIVE AGENTS, IMMUNE MONITORING STRATEGIES, LONG-TERM COMPLICATIONS SUCH AS CARDIAC ALLOGRAFT VASCULOPATHY, (CONTINUED ON SCHEDULE O)(CONTINUATION FROM FORM 990, PAGE 2)NOVEL METHODS FOR ORGAN PROCUREMENT AND PRESERVATION, NEW MECHANICAL CIRCULATORY SUPPORT DEVICES AND PULMONARY HYPERTENSION. THE ORGANIZATION ALSO SUPPORTS IMPORTANT SCIENTIFIC SYMPOSIA, WHICH ALLOW FOR THE EXCHANGE OF IDEAS AMONG LEADERS IN THE FIELD AND PROVIDE A FORUM FOR EXPERTS TO SHARE THEIR EXPERIENCE AND KNOWLEDGE WITH OTHER PRACTITIONERS. THE ORGANIZATION RESOURCES ARE ALSO LEVERAGED TO SUPPORT A SUMMER RESEARCH INTERNSHIP PROGRAM FOR UNDERGRADUATE STUDENTS WITH AN INTEREST IN MEDICINE AND/OR ACADEMIC RESEARCH. FOLLOWING IS A SUMMARY OF PROJECTS AND PROGRAMS IMPLEMENTED IN 2019: SCIENTIFIC FORUMS AND EDUCATIONAL ACTIVITIES:* "CUTTING EDGE OF TRANSPLANTATION (CEOT)" - FEBRUARY 21-23, 2019 (PHOENIX AZ)THIS CONFERENCE WAS ORGANIZED BY THE AMERICAN SOCIETY OF TRANSPLANTATION, WITH CONTENT DEVELOPED AROUND THE THEMATIC FOCUS OF "NO SIZE FITS ALL: UNCOVERING THE POTENTIAL OF PERSONALIZED TRANSPLANTATION". DEDICATED HEART AND LUNG SESSIONS WERE DESIGNED, ORGANIZED AND CHAIRED BY DR. KOBASHIGAWA, WITH A FOCUS ON CUSTOMIZED IMMUNOSUPPRESSION AND BIOMARKERS FOR ORGAN REJECTION. THE INTERACTIVE SESSIONS ATTRACTED 100 PARTICIPANTS AND INCLUDED A HIGHLY ACCLAIMED EXPERT FACULTY, A MENTORED CASE STUDY SESSION FOR FELLOWS AND NETWORKING OPPORTUNITIES.* "CONSENSUS CONFERENCE ON HEART/KIDNEY TRANSPLANTATION" - SATURDAY, JUNE 1ST, 2019 (BOSTON, MA)JOINTLY SPONSORED BY THE AST THORACIC AND CRITICAL CARE COMMUNITY OF PRACTICE, THE KIDNEY PANCREAS COMMUNITY OF PRACTICE, AND CEDARS-SINAI SMIDT HEART INSTITUTE, THIS CONSENSUS CONFERENCE WAS HELD JUST PRIOR TO THE 2019 AMERICAN TRANSPLANT CONGRESS. DESIGNED TO PROVIDE A FORUM FOR AN IN-DEPTH DISCUSSION AMONG THE LEADING EXPERTS IN THE FIELD, INCLUDING NEPHROLOGISTS, CARDIOLOGISTS, AND TRANSPLANT SURGEONS, THIS CONFERENCE SERVED AS A FIRST STEP IN DEVELOPING NEEDED GUIDELINES FOR THE INTERDISCIPLINARY CRITERIA FOR KIDNEY TRANSPLANTATION IN THE COMBINED HEART/KIDNEY TRANSPLANT CANDIDATE, EVALUATE THE CURRENT ALLOCATION OF KIDNEYS TO FOLLOW THE HEART FOR THE HEART/KIDNEY TRANSPLANT RECIPIENT AND RECOMMEND STANDARDIZED CARE FOR THE COLLABORATIVE MANAGEMENT OF HEART/KIDNEY TRANSPLANT RECIPIENTS. A CONSENSUS STATEMENT IS CURRENTLY BEING DRAFTED, WITH PUBLICATION EXPECTED BY THE END OF THIS CALENDAR YEAR.* CARDIAC AMYLOID CONSORTIA - INVESTIGATOR MEETINGS - MONDAY, MARCH 18TH, 2019 (NEW ORLEANS, LA) AND WEDNESDAY, APRIL 3RD, 2019 (ORLANDO, FL)TWO BRAINSTORMING MEETINGS REGARDING THE ESTABLISHMENT OF A CONSORTIUM TO SUPPORT A MULTI-CENTER AMYLOID REGISTRY WERE HELD IN TANDEM WITH THE AMERICAN COLLEGE OF CARDIOLOGY AND INTERNATIONAL SOCIETY OF HEART & LUNG TRANSPLANTATION IN THE SPRING OF THIS YEAR. BOTH MEETINGS WERE ORGANIZED BY DR. JIGNESH PATEL AND SPONSORED BY DR. JON KOBASHIGAWA. THE MEETINGS PROVIDED A FORUM FOR EXPERTS IN THIS RARE DISEASE TO DISCUSS AND DEVELOP A NEW CONSORTIUM TO PURSUE COLLABORATIVE RESEARCH, INCLUDING THE INITIATION OF A MULTI-CENTER REGISTRY STUDY.* OPTIMAL CARE AND NEW THERAPIES IN ADVANCED HEART DISEASE (LAS VEGAS, NV) SEPTEMBER 7TH, 2019THIS 1-DAY SYMPOSIUM ON ADVANCED HEART DISEASE TOOK PLACE ON SATURDAY, SEPTEMBER 7TH, 2019 AT THE MGM GRAND HOTEL CONFERENCE CENTER IN LAS VEGAS. THE PROGRAM FEATURED PRESENTATIONS ON TOPICS RELATED TO THE DIAGNOSIS AND TREATMENT OF HEART FAILURE, TRANSPLANTATION, MECHANICAL CIRCULATORY SUPPORT AND PULMONARY HYPERTENSION. THE PROGRAM WAS ATTENDED BY 40 PARTICIPANTS, INCLUDING COMMUNITY CARDIOLOGISTS IN THE LOCAL AREA.* DSL/THOMAS D. GORDON VISITING PROFESSOR IN ADVANCED HEART DISEASE (LOS ANGELES, CA) SEPTEMBER 23RD-24TH, 2019THIS YEAR'S VISITING PROFESSOR WAS DR. SHARON HUNT. WITH A CAREER AT STANFORD SPANNING OVER FIFTY YEARS, DR. HUNT HAS WITNESSED THE HISTORY OF HEART TRANSPLANT SURGERY FROM THE VERY FIRST ONE IN THE US BY NORMAN SHUMWAY IN 1968, THROUGH THE INTERNATIONAL MORATORIUM ON HEART TRANSPLANTS AND THE RECENT DECADES OF COMBINED HEART-LUNG TRANSPLANTS AND MECHANICAL ASSIST DEVICES. SHE IS A PAST PRESIDENT OF THE INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION AND RECEIVED THEIR LIFETIME ACHIEVEMENT AWARD IN 2012. SHE IS ALSO A MASTER OF THE AMERICAN COLLEGE OF CARDIOLOGY. HER TWO-DAY VISIT INCLUDED A GRAND ROUNDS LECTURE, NOON CONFERENCE PRESENTATION AND CASE STUDY PRESENTATIONS WITH CARDIOLOGY FELLOWS.* PRACTICUM IN MECHANICAL CIRCULATORY SUPPORT: MANAGING CARDIOGENIC SHOCK WITH SHORT TERM DEVICES (LOS ANGELES, CA) FRIDAY, OCTOBER 11TH, 2019 THIS 1-DAY SYMPOSIUM ON MECHANICAL CIRCULATORY SUPPORT WAS DEVELOPED IN COLLABORATION WITH CEDARS-SINAI OFFICE OF CONTINUING MEDICAL EDUCATION AND TOOK PLACE ON OCTOBER 11TH, 2019. THE PROGRAM INCLUDED INTERACTIVE DIDACTIC PRESENTATIONS, CASE STUDIES, AND WET-LAB EXPERIENCES, UTILIZING THE CEDARS-SINAI SIMULATION CENTER. THE PROGRAM ALSO FEATURED 5 EXPERT GUEST FACULTY FROM ACROSS THE UNITED STATES PLUS 12 INTERNAL FACULTY. THE PROGRAM DREW 103 ATTENDEES INCLUDING PHYSICIANS, ALLIED HEALTH PROFESSIONALS, NURSE PRACTITIONERS, AND TRANSPLANT COORDINATORS AND PROVIDED LEARNERS WITH A COMPREHENSIVE OVERVIEW OF MECHANICAL CIRCULATORY SUPPORT.* HEART TRANSPLANT VISITING SCIENTISTS: DURING THE LAST CALENDAR YEAR, DR. KOBASHIGAWA HOSTED AND MENTORED VISITING SCIENTISTS FROM OUTSIDE THE U.S., IN AN EFFORT TO FORGE RESEARCH COLLABORATIONS INTERNATIONALLY. VISITING SCIENTISTS SPEND UP TO ONE YEAR ON CAMPUS, DESIGNING AND COMPLETING RESEARCH PROJECTS FOR PUBLICATION AND PRESENTATION, UNDER HIS DIRECT SUPERVISION. IN THE LAST YEAR, THE FOLLOWING PHYSICIAN-INVESTIGATORS COMPLETED EXTENDED VISITS TO OUR PROGRAM:OSAMU SEGUCHI, MD (NATIONAL CEREBRAL & CARDIOVASCULAR CENTER, JAPAN)GUILLAUME COUTANCE, PHD (PARIS TRANSPLANT GROUP, FRANCE)JONG-CHAN YOUN, MD, PHD (SEOUL ST. MARY'S HOSPITAL COLLEGE OF MEDICINE, KOREA)* HEART TRANSPLANT PRECEPTORSHIPS: THROUGHOUT THE YEAR, WE RECEIVE REQUESTS TO PROVIDE EXTENDED OBSERVATIONAL TRAINING OPPORTUNITIES TO PHYSICIANS AND ADVANCE PRACTICE NURSES FROM VARIOUS INSTITUTIONS WITH AN INTEREST IN THE MANAGEMENT OF HEART TRANSPLANT AND MECHANICAL ASSIST DEVICE PATIENTS. IN THE LAST YEAR, WE HOSTED THE FOLLOWING VISITING PHYSICIANS:KIM JIN-JIN, MD (THE CATHOLIC UNIVERSITY OF KOREA, KOREA)CHOI HONG-MI, MD (HALLYM SACRED HEART HOSPITAL, KOREA)HONG JUNG-AE, MD (ASAN MEDICAL CENTER, UNIVERSITY OF ULSAN COLLEGE OF MEDICINE)PRECEPTORSHIPS GENERALLY TAKE PLACE OVER THE COURSE OF A WEEK, DEPENDING ON THE FOCUS OF THE TRAINING. TRAINING INCLUDES PARTICIPATION IN IN-HOSPITAL ROUNDS, OUT-PATIENT CLINIC VISITS, SURGERY/DEVICE IMPLANTATION OBSERVATIONS, DIDACTIC LECTURES, CASE STUDIES, JOURNAL CLUBS AND RESEARCH MEETINGS.* SUMMER RESEARCH INTERNSHIPS: UNDER THE SUPERVISION AND MENTORSHIP OF DR. JON KOBASHIGAWA, SUMMER HEART TRANSPLANT RESEARCH INTERNSHIPS HAVE BEEN OFFERED TO TEN STUDENTS FOR THE SUMMER OF 2019. THESE INTERNSHIPS PROVIDE STUDENTS AT ALL LEVELS OF TRAINING AN OPPORTUNITY TO LEARN THE CLINICAL RESEARCH PROCESS, INCLUDING MEDICAL LITERATURE REVIEW, STUDY DESIGN, CHART REVIEW/DATA COLLECTION, DATA ANALYSIS, AND ABSTRACT DEVELOPMENT AND SUBMISSION. COMPLETED ABSTRACTS WILL BE SUBMITTED TO THE AMERICAN FEDERATION OF MEDICAL RESEARCH, A FORUM FOR JUNIOR INVESTIGATORS. THIS YEAR'S GROUP INCLUDES STUDENTS FROM:UC IRVINE SCHOOL OF MEDICINESACKLER UNIVERSITY TEL AVIV MEDICAL SCHOOLRUSH MEDICAL COLLEGEWESTERN UNIVERSITY COLLEGE OF OSTEOPATHIC MEDICINECALIFORNIA STATE UNIVERSITY MORRO BAYUNIVERSITY OF CALIFORNIA, LOS ANGELESUNIVERSITY OF SOUTHERN CALIFORNIAUNIVERSITY OF CHICAGOUNIVERSITY OF CALIFORNIA, SANTA CRUZ* CURRENT TRENDS IN HEART TRANSPLANTATION: PATIENT EDUCATION SERIES"THIS PATIENT EDUCATION LECTURE BY DR. JON KOBASHIGAWA IS SCHEDULED TWICE A YEAR, COVERING CURRENT TRENDS IN HEART TRANSPLANTATION AND PROVIDING PATIENTS WITH AN OVERVIEW OF CUTTING-EDGE INNOVATIONS IN THE FIELD OF HEART TRANSPLANTATION. FORUMS WERE HELD ON JUNE 10TH, 2019 AND DECEMBER 11TH, 2019 AT THE MEDICAL CENTER AND ATTENDED BY POST-TRANSPLANT PATIENTS AS WELL AS PATIENTS ON THE WAITING LIST FOR TRANSPLANTATION.CLINICAL RESEARCH:THIS SECTION IS FORMATTED BY TITLE; PRINCIPAL INVESTIGATOR (PI); STATUS; SPONSOR. 1954029 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 13 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 X 5 3 0 0 0 0 1 1 1 1 1 0 0 0 1 1 1 0 0 0 1 0 CA X DEBBIE BOTTEN 3104238473 15821 VENTURA BLVD STE 520 ENCINO CA 91436 EDUARDO MARBAN MD DIRECTOR 1.00 60.00 X 0 3759190 230090 THOMAS D GORDON DIRECTOR 1.00 40.00 X 0 99500 159456 CHRISTINE SUMBI SECRETARY 40.00 0.00 X 0 222018 30661 IRINA COZIANU RESEARCH OPERATIONS MANAGER 40.00 0.00 X 0 133717 32715 VENISE STRAND PROGRAM MANAGER 40.00 0.00 X 0 104871 22793 PHYLLIS KATZ EXECUTIVE ASSISTANT 40.00 0.00 X 0 102399 22774 MARIA THOTTAM CLINICAL RESEARCH COORDINATOR II 40.00 0.00 X 0 100742 12892 JON KOBASHIGAWA MD PRESIDENT 2.00 0.00 X X 0 0 0 MICHELE HAMILTON TREASURER 2.00 0.00 X X 0 0 0 JAIME MORIGUCHI MD DIRECTOR 2.00 0.00 X 0 0 0 0 4522437 511381 0 0 1 0 0 1944292 1944292 EDUCATIONAL PROGRAMS 611430 256719 256719 CULTURAL PROGRAMS 611710 9585 9585 266304 2210596 266304 0 0 225698 225698 1155693 1155693 46438 46438 79580 79580 91950 91950 9985 6990 2995 2877 2589 288 352126 352126 220610 209580 11030 MEALS AND ENTERTAINMENT 9866 3354 6512 MOVING/STORAGE 2140 2140 BANK CHARGES 1800 1800 CREDIT CARD FEES 823 823 1741 966 775 2201327 1954029 247298 0 24760 71669 19015 7511 107678 107678 0 0 43775 79180 205011 228630 2982 5500 207993 234130 X -164218 -154950 -164218 -154950 43775 79180 X 9269 -1 X 0 0 0 X 1784016 1531356 1466549 1603657 1944292 8329870 1784016 1531356 1466549 1603657 1944292 8329870 8329870 1031 6 0 0 0 1037 8330907 1156187 0.99990 0.99920 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 70594 70594 0 37084 37084 0 0 0 1 0 0 0 0 0 0 0 EDUARDO MARBAN MD DIRECTOR 0 1906529 0 515772 0 1336889 0 196788 0 33302 0 3989280 0 600000 THOMAS D GORDON DIRECTOR 0 0 0 0 0 99500 0 159456 0 0 0 258956 0 0 CHRISTINE SUMBI SECRETARY 0 182307 0 33246 0 6465 0 18026 0 12635 0 252679 0 0 IRINA COZIANU RESEARCH OPERATIONS MANAGER 0 116591 0 17126 0 0 0 7448 0 25267 0 166432 0 0 PART I, LINE 3 PLEASE SEE SCHEDULE O NARRATIVE FOR PART VI, SECTION B LINE 15B. PART I, LINE 4B THE PLAN IS A SUPPLEMENTAL RETIREMENT ALLOWANCE THAT IS PAYABLE DIRECTLY TO THE PARTICIPANTS EACH QUARTER. THE BENEFIT FORMULA FOR THIS PLAN HAS ANNUAL CONTRIBUTIONS THAT ARE EITHER A PERCENTAGE OF SALARY, OR ARE DESIGNED TO FUND A PERCENTAGE OF THE ESTIMATED FINAL 5-YEAR AVERAGE SALARY. IN ADDITION, ONE INDIVIDUAL HAD RETENTION INCENTIVES WHICH HAD CLIFF-VESTING DATE IN 2019. THE FOLLOWING DIRECTOR AND OFFICER RECEIVED PAYMENTS DURING THE YEAR ENDED DECEMBER 31, 2019: CHRISTINE SUMBI 6,185 EDUARDO MARBAN, MD 1,166,914 FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE: (CONTINUED) A PILOT RANDOMIZED STUDY TO ASSESS THE EFFECT AND SAFETY PROFILE OF THYMOGLOBULIN IN PRIMARY CARDIAC TRANSPLANT RECIPIENTS: A 12-MONTH, SINGLE CENTER, RANDOMIZED OPEN-LABEL STUDY OF EFFICACY COMPARING IMMEDIATE TREATMENT WITH AND WITHOUT THYMOGLOBULIN 1.5MG/KG/D FOR 5 CONSECUTIVE DAYS IN HEART TRANSPLANT RECIPIENTS; KOBASHIGAWA; ENROLLING; SANOFI TARGETING INFLAMMATION AND ALLOIMMUNITY IN HEART TRANSPLANT RECIPIENTS WITH TOCILIZUMAB; KOBASHIGAWA; ENROLLING; NIH/MGH RISK FACTORS AND OUTCOMES IN ADVANCED HEART DISEASE (REGISTRY STUDY); KOBASHIGAWA; ENROLLING; INTERNAL KCCQ - QUALITY OF LIFE SURVEY STUDY; KOBASHIGAWA; ENROLLING; INTERNAL CARDIAC SURGERY AFTER HEART TRANSPLANTATION - AN EXPLORATORY, RETROSPECTIVE, MULTICENTER STUDY (CASH-STUDY);KOBASHIGAWA; FINAL ANALYSIS PENDING; MEDICAL UNIVERSITY OF VIENNA EXTERNAL FACTORS AND OUTCOMES FOR HEART TRANSPLANT RECIPIENTS: A SINGLE CENTER SURVEY STUDY; KOBASHIGAWA; ENROLLING; INTERNAL SURVEILLANCE HEARTCARE OUTCOMES REGISTRY STUDY (SHORE); KOBASHIGAWA; ENROLLING; CAREDX A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY (GALACTIC-HF) ASSESS THE EFFICACY AND SAFETY OF OMECAMTIV MECARBIL ON MORTALITY AND MORBIDITY IN SUBJECTS WITH CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION; CHANG; ENROLLMENT AND FOLLOW-UP VISITS COMPLETE; PENDING DATA LOCK AND ANALYSIS; AMGEN A DOUBLE-BLIND, RANDOMIZED, SHAM-PROCEDURE-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY STUDY OF ALLOGENEIC MESENCHYMAL PRECURSOR CELLS IN PATIENTS WITH CHRONIC HEART FAILURE DUE TO LEFT VENTRICULAR SYSTOLIC DYSFUNCTION OF EITHER ISCHEMIC OR NON ISCHEMIC ETIOLOGY: DREAM HF-1; CHANG; ENROLLMENT AND FOLLOW-UP VISITS COMPLETE; PENDING DATA LOCK AND ANALYSIS; MESOBLAST, INC. RANDOMIZED CONTROLLED PIVOTAL TRIAL OF AUTOLOGOUS BONE MARROW MONONUCLEAR CELLS USING THE CARDIAMP CELL THERAPY IN PATIENTS WITH POST MYOCARDIAL INFARCTION HEART FAILURE (CARDIAMP HEART FAILURE TRIAL); CHANG; ENROLLING; BIOCARDIA CONTINUED ACCESS PROTOCOL TO COLLECT ADDITIONAL EVIDENCE TO EVALUATE THE SAFETY AND EFFECTIVENESS OF THE PORTABLE ORGAN CARE SYSTEM (OCS) HEART FOR PRESERVING AND ASSESSING EXPANDED CRITERIA DONOR HEARTS FOR TRANSPLANTATION (HEART EXPAND CAP); ESMAILIAN; ENROLLING; TRANSMEDICS HEART INSTITUTE BIOBANK STUDY; HAMILTON; ENROLLING; INTERNAL RELIEVE-HF TRIAL: REDUCING LUNG CONGESTION SYMPTOMS USING THE V-WAVE SHUNT IN ADVANCED HEART FAILURE; HAMILTON; ENROLLING; V-WAVE THE FREQUENCY AND SIGNIFICANCE OF BLOOD TYPE A1 DONORS TO NON-A1 SUBGROUP RECIPIENTS IN HEART TRANSPLANTATION; KITTLESON; ENROLLING; INTERNAL TRANSPLANT OF REDEEMED ORGANS BY JUDICIOUS ADMINISTRATION OF NEW DIRECT-ACTING ANTIVIRALS FOR HEPATITIS-C HEART RECIPIENTS (TROJAN-C); KRANSDORF; ENROLLING; BAYLOR UNIVERSITY/ONE LEGACY HEART FAILURE CLINICAL RESEARCH NETWORK ENTRESTO (LCZ696) IN ADVANCED HEART FAILURE (LIFE STUDY); KRANSDORF; ENROLLMENT AND FOLLOW-UP VISITS COMPLETE; PENDING DATA LOCK AND ANALYSIS; DUKE UNIVERSITY DILATED CARDIOMYOPATHY (DCM) RESEARCH PROJECT; KRANSDORF; ENROLLING; OHIO UNIVERSITY B3461045: A PHASE 3 MULTICENTER, OPEN LABEL STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826-83) 20 MG OR 80 MG [OR TAFAMIDIS (PF-06291826-00) 61 MG] IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (ATTR-CM); PATEL; ENROLLMENT COMPLETE; FOLLOW-UP VISITS ONLY; PFIZER CARDIAC AMYLOIDOSIS REGISTRY STUDY; PATEL; ENROLLING; INTERNAL FORM 990, PART IV, LINE 12 THE ORGANIZATION WAS INCLUDED IN A CONSOLIDATED, INDEPENDENT AUDITED FINANCIAL STATEMENTS FOR THE FISCAL YEARS ENDED 6/30/19 AND 6/30/20 DUE TO THE FACT THAT THE TAX YEAR OF ITS TAX-EXEMPT PARENT ORGANIZATION, CEDARS-SINAI MEDICAL CENTER, ENDS ON 6/30. THERE ARE NO AUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 12/31/19. FORM 990, PART VI, SECTION A, LINE 6 CEDARS-SINAI MEDICAL CENTER IS THE SOLE CORPORATE MEMBER OF CALIFORNIA HEART CENTER FOUNDATION. FORM 990, PART VI, SECTION A, LINE 7A CEDARS-SINAI MEDICAL CENTER AS THE SOLE CORPORATE MEMBER, CAN ELECT BOARD OF DIRECTORS TO CALIFORNIA HEART CENTER FOUNDATION. FORM 990, PART VI, SECTION A, LINE 7B RESERVED RIGHTS OF CEDARS-SINAI MEDICAL CENTER, THE SOLE CORPORATE MEMBER OF THE ORGANIZATION. THE FOLLOWING ACTIONS MUST BE APPROVED OR ACTED UPON BY CEDARS-SINAI MEDICAL CENTER BEFORE BECOMING EFFECTIVE: (A) ANY SALE OR OTHER DISPOSITION OF ALL OR A SUBSTANTIAL PORTION OF THE ASSETS OF THE ORGANIZATION; (B) ANY MERGER OR AFFILIATION OF THE ORGANIZATION WITH ANY PERSON OR ENTITY OTHER THAN THE MEMBER; (C) ANY AMENDMENT TO THE ARTICLES OF INCORPORATION OR BYLAWS OF THE ORGANIZATION; (D) ANY ACT OR OMISSION WHICH CREATES ANY MATERIAL RISK TO THE MEMBER'S TAX EXEMPT STATUS, OR CREATES ANY MATERIAL RISK OF A VIOLATION OF ANY STATE OR FEDERAL LAWS; (E) DISSOLUTION OF THE ORGANIZATION OR THE FILING OF ANY BANKRUPTCY PETITION; (F) CREATION OF ANY NEW CORPORATION, PARTNERSHIP OR ASSOCIATION; (G) ACQUISITION OF OR THE INVESTMENT IN A NEW OPERATING BUSINESS; (H) ENTERING INTO ANY PARTNERSHIPS OR JOINT VENTURES; (I) ADOPTION OF OR CHANGES TO OPERATING OR CAPITAL BUDGETS; (J) ADOPTION OF THIS CORPORATION'S POLICIES AND PROCEDURES; (K) EXECUTION AND DELIVERY OF ANY NEW AFFILIATION AGREEMENTS AND OTHER RELATIONSHIPS WITH THE UCLA SCHOOL OF MEDICINE AND OTHER INSTITUTIONS OF MEDICAL LEARNING; (L) UNBUDGETED CAPITAL EXPENDITURES OVER $100,000; (M) LOANS, BORROWINGS OR GUARANTEES IN EXCESS OF $100,000, UNLESS APPROVED IN THE BUDGET; (N) ANY SECURITY INTERESTS OR MORTGAGES ON THE PROPERTY OF ORGANIZATION; (O) OPERATING OR CAPITAL LEASES WHERE THE TERM IS OVER FIVE YEARS OR THE TOTAL OBLIGATION UNDER THE LEASE EXCEEDS $100,000, UNLESS APPROVED IN THE BUDGET; (P) TERMINATION OR SELECTION OF THE AUDITORS OF THE ORGANIZATION; (Q) APPOINTMENT OR REMOVAL OF ANY MEMBER OF THE BOARD (OTHER THAN EX-OFFICIO DIRECTORS); (R) APPOINTMENT OF REMOVAL OF ANY OFFICERS; (S) EXECUTION AND DELIVERY OF ANY PROFESSIONAL SERVICE AGREEMENTS; (T) RELOCATION OF PRINCIPAL OFFICE; AND (U) FIXING THE NUMBER OF DIRECTORS OF THE ORGANIZATION. FORM 990, PART VI, SECTION B, LINE 11B THE ORGANIZATION'S FORM 990 UNDERGOES AN INTENSE AND HIGHLY COMPREHENSIVE REVIEW PROCESS. THE REVIEW INVOLVES VARIOUS MANAGEMENT PERSONNEL AND A BIG FOUR ACCOUNTING FIRM. FORM 990, PART VI, SECTION B, LINE 12C CONFLICT OF INTEREST POLICY ANNUAL STATEMENTS: EACH DIRECTOR, OFFICER, MEMBER OF A COMMITTEE WITH BOARD-DELEGATED POWERS AND ANY OTHER INTERESTED PERSON AS DETERMINED BY THE BOARD OR COMMITTEE SHALL AT LEAST ANNUALLY SIGN A COPY OF THE "STATEMENT PERTAINING TO CONFLICT OF INTEREST." IF A DIRECTOR, OFFICER, OR COMMITTEE MEMBER, OR DESIGNATED INTERESTED PERSON BECOMES AWARE THAT A POTENTIAL OR APPARENT CONFLICT MAY EXIST WHICH IS NOT DISCLOSED ON SUCH A STATEMENT, IT SHALL BE THE RESPONSIBILITY OF THE INTERESTED PERSON TO DISCLOSE THE POTENTIAL CONFLICT TO THE PRESIDENT AND TO THE BOARD OR APPROPRIATE COMMITTEE AND AS SET FORTH ABOVE, PRIOR TO ANY BOARD OR COMMITTEE DISCUSSIONS OR ACTION WITH RESPECT TO THE RELEVANT TRANSACTION OR ARRANGEMENT, AND, IF RELEVANT, TO LEAVE THE MEETING DURING THE DISCUSSION AND VOTE ON THE TRANSACTION OR ARRANGEMENT. DETERMINING WHETHER A CONFLICT OF INTEREST EXISTS: IF CONSIDERATION OF THE TRANSACTION OR ARRANGEMENT AT ISSUE IS A MATTER WITHIN THE SCOPE OF AUTHORITY OF THE BOARD OF DIRECTORS OR A COMMITTEE, AFTER DISCLOSURE OF THE FINANCIAL INTEREST AND AFTER ANY DISCUSSION WITH THE INTERESTED PERSON, THE RELEVANT CALIFORNIA HEART CENTER FOUNDATION ("CHCF") OFFICER OR ADMINISTRATOR SHALL DETERMINE WHETHER A CONFLICT OF INTEREST EXISTS. IF IT IS DETERMINED THAT A CONFLICT OF INTEREST EXISTS AND, NOTWITHSTANDING THE CONFLICT, THE CHCF OFFICER OR ADMINISTRATOR DETERMINES THAT IT CONTINUES TO BE IN THE BEST INTERESTS OF CHCF TO PROCEED WITH THE TRANSACTION OR ARRANGEMENT AT ISSUE, THE CHCF OFFICER OR ADMINISTRATOR SHALL REFER THE TRANSACTION OR ARRANGEMENT TO THE BOARD OR THE APPROPRIATE BOARD-DESIGNATED COMMITTEE FOR EVALUATION. ALTERNATIVELY IF CONSIDERATION OF THE TRANSACTION OR ARRANGEMENT AT ISSUE IS A MATTER WITHIN THE SCOPE OF THE AUTHORITY OF THE BOARD OF DIRECTORS OR A COMMITTEE, THE INTERESTED PERSON SHALL LEAVE THE BOARD OR COMMITTEE MEETING WHILE THE DETERMINATION OF THE EXISTENCE OF A CONFLICT OF INTEREST IS DISCUSSED AND VOTED UPON. THE REMAINING BOARD OR COMMITTEE MEMBERS SHALL DECIDE, BY MAJORITY VOTE, IF A CONFLICT OF INTEREST EXISTS. PROCEDURES FOR ADDRESSING THE CONFLICT OF INTEREST: A. AN INTERESTED PERSON MAY MAKE A PRESENTATION TO THE BOARD OR COMMITTEE REGARDING THE TRANSACTION OR ARRANGEMENT. AFTER SUCH PRESENTATION THE INTERESTED PERSON MUST LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON THE TRANSACTION OR ARRANGEMENT. B. THE CHAIR OF THE BOARD OR COMMITTEE SHALL, IF DEEMED APPROPRIATE BY THE BOARD OR COMMITTEE, APPOINT A DISINTERESTED PERSON OR COMMITTEE TO INVESTIGATE ALTERNATIVES TO THE PROPOSED TRANSACTION OR ARRANGEMENT. C. AFTER EXERCISING DUE DILIGENCE, THE BOARD OR COMMITTEE SHALL DETERMINE WHETHER CHCF CAN OBTAIN A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT WITH REASONABLE EFFORTS FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. D. IF A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT IS NOT REASONABLY ATTAINABLE UNDER CIRCUMSTANCES THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST, THE BOARD OR COMMITTEE SHALL DETERMINE BY A MAJORITY VOTE OF THE DISINTERESTED DIRECTORS WHETHER THE TRANSACTION OR ARRANGEMENT IS IN CHCF' BEST INTEREST AND FOR ITS OWN BENEFIT AND WHETHER THE TRANSACTION IS FAIR AND REASONABLE TO CHCF AND SHALL MAKE ITS DECISION AS TO WHETHER TO ENTER INTO THE TRANSACTION OR ARRANGEMENT IN CONFORMITY WITH SUCH DETERMINATION. VIOLATIONS OF THE CONFLICTS POLICY: A. IF THE BOARD OR COMMITTEE HAS REASONABLE CAUSE TO BELIEVE THAT A MEMBER OF THE BOARD OR COMMITTEE OR AN OFFICER OR OTHER INTERESTED PERSON HAS FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL INFORM THE MEMBER OR OFFICER OR INTERESTED PERSON OF THE BASIS FOR SUCH BELIEF AND AFFORD SUCH PERSON AN OPPORTUNITY TO EXPLAIN THE ALLEGED FAILURE TO DISCLOSE. B. IF, AFTER HEARING THE RESPONSE OF SUCH PERSON AND MAKING SUCH FURTHER INVESTIGATION AS MAY BE WARRANTED IN THE CIRCUMSTANCES, THE BOARD OR COMMITTEE DETERMINES THAT SUCH PERSON HAS IN FACT FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL TAKE APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION. FORM 990, PART VI, SECTION B, LINE 15B THE EXECUTIVE PERSONNEL COMMITTEE (THE COMMITTEE) OF THE TAX-EXEMPT PARENT OF THE ORGANIZATION, CEDARS-SINAI MEDICAL CENTER, IS A STANDING COMMITTEE OF THE BOARD OF DIRECTORS. THE COMMITTEE ADDRESSES COMPENSATION AND BENEFITS REGARDING THE ORGANIZATION'S CHIEF FINANCIAL OFFICER AND BOARD MEMBERS WHO ARE ALSO EXECUTIVE EMPLOYEES AND CONTRACTUALLY ENGAGED FACULTY OF THE MEDICAL CENTER, AND IS AUTHORIZED BY THE BOARD OF DIRECTORS TO ACT ON BEHALF OF THE BOARD WITH RESPECT TO SUCH ISSUES, AND OTHER GOVERNANCE ISSUES AS REQUESTED BY THE BOARD OF DIRECTORS, THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS, THE CHAIR OF THE BOARD OF DIRECTORS, OR THE CEO, ALL SUBJECT TO THE COMMITTEE'S ONGOING REPORTING OBLIGATION TO THE BOARD OF DIRECTORS OR THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS. SPECIFICALLY, THE COMMITTEE EVALUATES THE PERFORMANCE AND APPROVES THE COMPENSATION AND BENEFITS FOR THE ORGANIZATION'S CHIEF FINANCIAL OFFICER AND BOARD MEMBERS WHO ARE ALSO EXECUTIVE EMPLOYEES AND CONTRACTUALLY ENGAGED FACULTY OF THE MEDICAL CENTER. THE MEMBERS OF THE COMMITTEE ARE APPOINTED ANNUALLY BY THE CHAIR OF THE MEDICAL CENTER'S BOARD OF DIRECTORS. APPOINTMENTS ARE FOR A ONE YEAR TERM. EACH YEAR, THE COMMITTEE FOLLOWS A PROCESS THAT ENSURES THAT THE COMPENSATION AND BENEFITS IS REASONABLE AND IN COMPLIANCE WITH APPLICABLE LAWS AND REGULATIONS. THE MEDICAL CENTER'S SVP OF HR PROVIDES STAFF SUPPORT TO THE COMMITTEE. THE COMMITTEE MAY INCLUDE MEMBERS OF THE MEDICAL CENTER'S MANAGEMENT TEAM OR ANY OTHER PERSON WHOSE PRESENCE THE COMMITTEE BELIEVES TO BE DESIRABLE OR APPROPRIATE. THE COMMITTEE MAY ENGAGE AN INDEPENDENT COMPENSATION AND BENEFITS CONSULTANT AND ANY OTHER ADVISORS THEY DEEM NECESSARY. THE COMMITTEE MAY ALSO ENGAGE INDEPENDENT COUNSEL. THE MEDICAL CENTER WILL PROVIDE FOR APPROPRIATE FUNDING FOR PAYMENT OF COSTS TO ANY SUCH PERSONS RETAINED BY THE COMMITTEE. ANNUALLY, AT THE COMMITTEE'S DIRECTION, THE INDEPENDENT COMPENSATION CONSULTANT SHALL PREPARE SUCH REPORTS AS THE COMMITTEE REASONABLY DEEMS NECESSARY. AT A MINIMUM, SUCH REPORTS WILL INCLUDE MARKET SURVEY DATA FROM A PEER GROUP DESIGNATED BY THE COMMITTEE, WHICH SHALL BE CONSIDERED BY THE COMMITTEE PRIOR TO MAKING DECISIONS. THE COMMITTEE MEETS AS FREQUENTLY AS THE COMMITTEE DEEMS NECESSARY AND WILL MAINTAIN WRITTEN MINUTES OF ITS MEETING. THE COMPENSATION AND BENEFITS OF THE PRESIDENT AND VICE-PRESIDENT ARE DETERMINED BY THE CHIEF FINANCIAL OFFICER OF THE ORGANIZATION WITH ASSISTANCE FROM HR WHICH PROVIDES AN INDEPENDENT REVIEW OF COMPARABLES. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, ITS CONFLICT OF INTEREST POLICY AND ITS TAX-EXEMPT PARENT'S AUDITED FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON WRITTEN REQUEST. FORM 990, PART XI, LINE 9: ROUNDING -1. CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BOULEVARD LOS ANGELES CA 90048 951644600 ACUTE-CARE, TEACHING AND RESEARCH HOSPITAL CA 501(C)(3) LINE 3 CEDARS-SINAI HEALTH SYSTEM 0 CEDARS-SINAI MEDICAL CARE FOUNDATION 15821 VENTURA BLVD STE 520 ENCINO CA 91436 954457756 PROVISION OF MEDICAL CARE, TEACHING AND RESEARCH CA 501(C)(3) LINE 12A, I CEDARS-SINAI MEDICAL CENTER 1 KERLAN-JOBE ORTHOPAEDIC FOUNDATION 6801 PARK TERRACE 500 LOS ANGELES CA 90045 954707606 EDUCATION AND RESEARCH RELATED TO ORTHOPAEDIC MEDICINE CA 501(C)(3) LINE 7 CEDARS-SINAI MEDICAL CARE FOUNDATION 1 SANTA MONICA ORTHOPAEDIC & SPORTS MED RESEARCH FDN 2020 SANTA MONICA BLVD 4TH FLR SANTA MONICA CA 90404 954789926 EDUCATION AND RESEARCH RELATED TO ORTHOPAEDIC AND NEUROLOGIC CONDITIONS CA 501(C)(3) PF CEDARS-SINAI MEDICAL CARE FOUNDATION 1 CFHS HOLDINGS INC 4650 LINCOLN BLVD MARINA DEL REY CA 90292 201645949 HEALTHCARE CA 501(C)(3) LINE 3 CEDARS-SINAI MEDICAL CENTER 1 CEDARS-SINAI HEALTH SYSTEM 8700 BEVERLY BOULEVARD LOS ANGELES CA 90048 300990905 SUPPORT SPECIFIED NONPROFIT HEALTHCARE ORGANIZATIONS CA 501(C)(3) LINE 12C, III-FI N/A 0 TORRANCE HEALTH ASSOCIATION 23326 HAWTHORNE BLVD STE 300 TORRANCE CA 90505 330073515 HEALTH SERVICES CA 501(C)(3) LINE 12B, II CEDARS-SINAI HEALTH SYSTEM 1 TORRANCE MEMORIAL MEDICAL CENTER HEALTH CARE FOUNDATION 3330 LOMITA BLVD TORRANCE CA 90505 953528452 FUNDRAISING CA 501(C)(3) LINE 7 TORRANCE HEALTH ASSOCIATION 1 TORRANCE MEMORIAL MEDICAL CENTER 3330 LOMITA BLVD TORRANCE CA 90505 951644042 HEALTH SERVICES CA 501(C)(3) LINE 3 TORRANCE HEALTH ASSOCIATION 1 ENDOSCOPY CENTER OF SANTA MONICA LLC 12400 WILSHIRE BLVD STE 100 LOS ANGELES CA 90025 113652210 ENDOSCOPIES AND RELATED PROCEDURES CA N/A ISS ASC HOLDINGS LLC 200 N ROBERTSON BLVD STE 101 BEVERLY HILLS CA 90211 471890805 INVESTMENT IN HEALTHCARE SERVICES CA N/A DEL REY SURGERY INVESTORS LLC 6500 WILSHIRE BLVD 9TH FL LOS ANGELES CA 90048 364756208 INVESTMENT IN AMBULATORY SURGERY CENTER DE N/A DEL REY SURGERY CENTER LLC 6500 WILSHIRE BLVD 9TH FL LOS ANGELES CA 90048 462305372 AMBULATORY SURGERY CENTER CA N/A CS-BH ASC HOLDINGS LLC 200 N ROBERTSON BLVD STE 101 BEVERLY HILLS CA 90211 812246488 HOLDING COMPANY CA N/A INTERNATIONAL SPINE & ORTHOPEDIC INSTITUTE LLC 8500 W 110TH ST OVERLAND PARK KS 66210 263738893 SPINE AND ORTHOPEDIC INSTITUTE DE N/A SANTA MONICA IMAGING GROUP LLC 200 N ROBERTSON BLVD STE 101 BEVERLY HILLS CA 90211 820760657 IMAGING CENTER CA N/A TORRANCE MEMORIAL SURGICAL CENTER LLC I 23560 CRENSHAW BLVD STE 104 TORRANCE CA 90505 465259260 OUTPATIENT SURGICAL SERVICES CA N/A 3565 DEL AMO ASSOCIATES A CALIFORNIA LIMITED PARTNERSHIP 5017 CARMEN STREET TORRANCE CA 90503 330554737 RENTAL REAL ESTATE CA N/A 90210 ASC VENTURE LLC 200 N ROBERTSON BLVD STE 101 BEVERLY HILLS CA 90211 134341801 AMBULATORY SURGERY CENTER CA N/A OPTIMATRIX HEALTH SOLUTIONS INC 6500 WILSHIRE BLVD 9TH FLR LOS ANGELES CA 90048 954522779 INACTIVE CA N/A C 1 CENTINELA FREEMAN HOLDINGS INC 8700 BEVERLY BLVD STE TSB-290 LOS ANGELES CA 90048 593811890 REAL ESTATE RENTALS CA N/A C 1 OTOHARMONICS CORPORATION 411 SW 6TH AVE PORTLAND OR 97204 461119421 HEALTHCARE PRODUCT DEVELOPMENT DE N/A C 1 0 0 1 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0